Cargando…

Salvage therapy of pretreated advanced breast cancer with bevacizumab and paclitaxel every two weeks: a retrospective case review study

BACKGROUND: Targeting angiogenesis is nowadays one of the most promising approaches for breast cancer. Bevacizumab (BEV), a VEGF-trap monoclonal antibody, was recently approved in combination with paclitaxel (PAC) for the first line treatment of advanced breast cancer (ABC). The activity of this com...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ardavanis, Alexandros, Doufexis, Dimitrios, Kountourakis, Panteleimon, Malliou, Savvoula, Karagiannis, Athanasios, Kardara, Evgenia, Sykoutri, Despina, Charalampia, Margari, Rigatos, Gerasimos
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2759965/ https://www.ncbi.nlm.nih.gov/pubmed/19775466 http://dx.doi.org/10.1186/1471-2407-9-338

Ejemplares similares

Bilateral De Quervain Syndrome after Aromatase Inhibitor Administration: A Case Report and Review of the Literature
por: Papadimitriou, Konstantinos, et al.
Publicado: (2012)

Intelligent renewable energy systems: modelling and control
por: Rigatos, Gerasimos
Publicado: (2016)

State-space approaches for modelling and control in financial engineering: systems theory and machine learning methods
por: Rigatos, Gerasimos G
Publicado: (2017)

Nonlinear control and filtering using differential flatness approaches: applications to electromechanical systems
por: Rigatos, Gerasimos G
Publicado: (2015)

Advanced models of neural networks: nonlinear dynamics and stochasticity in biological neurons
por: Rigatos, Gerasimos G
Publicado: (2015)

Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study
por: Ardavanis, A, et al.
Publicado: (2005)

Propranolol and Weekly Paclitaxel in the Treatment of Metastatic Heart Angiosarcoma
por: Fiste, Oraianthi, et al.
Publicado: (2020)

Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastoma
por: Cuncannon, Moire, et al.
Publicado: (2019)

Chromogranin A as a valid marker in oncology: Clinical application or false hopes?
por: Gkolfinopoulos, Stavros, et al.
Publicado: (2017)

Pretreatment inflammatory indices predict Bevacizumab response in recurrent Glioma
por: Martínez-González, Alicia, et al.
Publicado: (2020)

Advances in molecular, genetic and immune signatures of gastric cancer: Are we ready to apply them in our patients’ decision making?
por: Gkolfinopoulos, Stavros, et al.
Publicado: (2018)

Docetaxel as Salvage Therapy in Highly Pretreated and Drug Resistant Gastrointestinal Carcinomas
por: Sprinzl, Martin F., et al.
Publicado: (2008)

Bevacizumab Exacerbates Paclitaxel-Induced Neuropathy: A Retrospective Cohort Study
por: Matsuoka, Ayumu, et al.
Publicado: (2016)

Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer
por: Geva, Ravit, et al.
Publicado: (2013)

Bevacizumab-based treatment as salvage therapy in patients with recurrent symptomatic brain metastases
por: Berghoff, Anna Sophie, et al.
Publicado: (2020)

Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non–Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer
por: Rosen, Virginia M., et al.
Publicado: (2017)

Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients
por: Vici, Patrizia, et al.
Publicado: (2013)

Selinexor, Bortezomib and Dexamethasone: An Effective Salvage Regimen for Heavily Pretreated Myeloma Patients
por: Delforge, Michel, et al.
Publicado: (2022)

A Case of Biphasic Pulmonary Blastoma Treated with Carboplatin and Paclitaxel plus Bevacizumab
por: Sakata, Shinya, et al.
Publicado: (2015)

Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers
por: Sen, Shiraj, et al.
Publicado: (2018)

A pharmacogenetic interaction analysis of bevacizumab with paclitaxel in advanced breast cancer patients
por: Coltelli, Luigi, et al.
Publicado: (2022)

Outcomes of 556 consecutive patients with stage I-III colon cancer managed in a single center over 10 years
por: Xenophontos, Eleni, et al.
Publicado: (2021)

Paclitaxel, ifosfamide, and cisplatin (TIP) as salvage and consolidation chemotherapy for advanced germ cell tumor
por: Kurobe, Masahiro, et al.
Publicado: (2014)

Weekly Paclitaxel plus Capecitabine versus Docetaxel Every 3 Weeks plus Capecitabine in Metastatic Breast Cancer
por: Wist, E. A., et al.
Publicado: (2012)

A single-arm study evaluating bevacizumab, cisplatin, and paclitaxel followed by single-agent bevacizumab in Japanese patients with advanced cervical cancer
por: Sugiyama, Toru, et al.
Publicado: (2017)

Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia
por: Schlenk, R F, et al.
Publicado: (2017)

Single-agent rituximab is an effective salvage therapy in pretreated patients with hairy cell leukemia
por: Broccoli, Alessandro, et al.
Publicado: (2023)

Paclitaxel, vinorelbine and 5-fluorouracil in breast cancer patients pretreated with adjuvant anthracyclines
por: Berruti, A, et al.
Publicado: (2005)

Comparison of Neoadjuvant Chemotherapy Efficiency in Advanced Ovarian Cancer Patients Treated With Paclitaxel Plus Carboplatin and Intraperitoneal Bevacizumab vs. Paclitaxel With Carboplatin
por: Tao, Yin, et al.
Publicado: (2022)

Favorable outcomes of adequate laser photocoagulation and salvage bevacizumab treatment for aggressive posterior retinopathy of prematurity
por: Fukushima, Yoko, et al.
Publicado: (2018)

RT-01 Treatment results of salvage gamma knife and bevacizumab (AVAgamma therapy) for recurrent glioblastoma
por: Sato, Kenichi, et al.
Publicado: (2020)

Diverticular Bleeding of the Colon during Combination Chemotherapy with Bevacizumab and Paclitaxel for Recurrent Breast Cancer
por: Nakayama, Yoshie, et al.
Publicado: (2013)

Two Cases of Mastectomy after Paclitaxel + Bevacizumab Therapy for Locally Advanced Breast Cancer
por: Shinoda, Chika, et al.
Publicado: (2014)

Paclitaxel, Carboplatin, and Bevacizumab in Advanced Cervical Cancer: A Treatment Response and Safety Analysis
por: Tao, Wanjun, et al.
Publicado: (2020)

The efficacy and safety of paclitaxel plus bevacizumab therapy in breast cancer patients with visceral crisis
por: Funasaka, Chikako, et al.
Publicado: (2021)

A Case of Pneumothorax Required Surgical Treatment as a Complication of Paclitaxel with Bevacizumab Treatment
por: Moriya, Yumi, et al.
Publicado: (2023)

Bevacizumab-Induced Thrombotic Microangiopathy (TMA) in Metastatic Lung Adenocarcinoma Patients Receiving Nivolumab Combined with Bevacizumab, Carboplatin and Paclitaxel: Two Case Reports
por: Hsu, Ping-Chih, et al.
Publicado: (2023)

Real-world efficacy and safety of bevacizumab single-maintenance therapy following platinum-paclitaxel chemotherapy plus bevacizumab in patients with advanced cervical cancer
por: Kotaka, Saki, et al.
Publicado: (2023)

Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas
por: Kountourakis, Panteleimon, et al.
Publicado: (2006)

Salvage Chemotherapy with Cisplatin, Ifosfamide, and Paclitaxel in Aggressive Variant of Metastatic Castration-Resistant Prostate Cancer
por: von Amsberg, Gunhild, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jj0s84bcue11g6e3lckrqbaavj